Abrocitinib Related Compound 3
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

Abrocitinib Related Compound 3

● Under Development

Catalogue No.:VL5020004
CAS No.:N/A
Mol. Formula:C11H15N5
Mol. Weight:217.28 g/mol

Additional information on Abrocitinib Related Compound 3

Parent drug

Abrocitinib

IUPAC Name

(1s, 3s)-N1-methyl-N1-(7H-pyrrolo[2, 3-d]pyrimidin-4-yl)cyclobutane-1, 3-diamine

Synonyms

N/A

Description

Abrocitinib Related Compound 3 Or (1s,3s)-N1-methyl-N1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)cyclobutane-1,3-diamine, Abrocitinib Related Compound 3 is an impurity present in Abrocitinib. Abrocitinib affects by blocking the signaling of pro-inflammatory cytokines, which are implicated in atopic dermatitis. Abrocitinib is a Janus kinase inhibitor, which is used for the treatment of atopic dermatitis.

References

Nezamololama, N., Fieldhouse, K., Metzger, K., & Gooderham, M. (2020). Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs in Context, 9, 1–7. https://doi.org/10.7573/dic.2020-8-5

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url